|
Covered Companies
Cel-Sci Corporation - CVMThe WHO (I'm not kidding- World Health Organization) has officially declared the Swine Flu as a world wide pandemic. This past week, the WHO raised the Swine Flu to "Phase 6", it's highest level for global risk. The Phase 6 alert does not mean the severity is increasing- it means the spread is more global. The Phase 6 ranking opens the door to accelerated production and research on a number of possible therapies and vaccines. One company getting major recognition for a possible therapy is AMEX listed Cel-Sci (AMEX: CVM), a stock I have been following on and off for many years. Last week, CVM announced its L.E.A.P.S (Ligand Epitope Antigen Presentation System) technology, could represent an immune based therapy for swine flu, and had shown promise. At the Naval Medical Research Center in Silver Spring, MD, L.E.A.P.S has demonstrated an ability to enhance the body's natural protection against many different kinds of diseases. The Navy is focused on using the therapy to treat Malaria. This past week, Cel-Sci announced it was developing an immune based treatment for the Swine Flu, and the stock went absolutely ballistic. Cel-Sci traded 32 million shares in one day last week, the highest volume in its more than 20 years of being a publicly traded company under the ticker CVM. CVM also surged from about $.25 to $.80 in one day. Pretty crazy.
Quote Data
Business SummaryCEL-SCI Corporation, a biotechnology company, engages in research and development of drugs and vaccines for the treatment of cancer and infectious diseases. The company’s primary product Multikine is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines under phase II clinical trail for the treatment of cancer. It also develops CEL-1000 peptide product with its Ligand Epitope Antigen Presentation System technology which is under preclinical stage for the protection/treatment of animals against herpes, malaria, viral encephalitis, and cancer. The company markets its products to cancer centers, physicians, and clinics involved in immunotherapy. CEL-SCI was founded in 1983 and is based in Vienna, Virginia.
Disclosure
TGR Group LLC, an affiliate of MarketByte LLC, has been paid a fee of 100,000 newly issued restricted shares by Cel-Sci Corporation, for coverage of the Company.
Recent News HeadlinesFri, 12 Mar 2010 21:46:27 Etc/GMT Fri, 12 Mar 2010 12:00:00 Etc/GMT Wed, 10 Mar 2010 15:30:00 Etc/GMT CEL-SCI Corporation announced today that it has received a $125,000 payment from Byron Biopharma under its licensing agreement where CEL-SCI granted Byron an exclusive license to market and distribute the Company's cancer drug Multikine® in the Republic of South Africa . Mon, 22 Feb 2010 14:45:00 Etc/GMT CEL-SCI Corporation and their scientific collaborators announced today that the Company's CEL-2000 vaccine demonstrated that it is able to block the progression of rheumatoid arthritis in a mouse model.  The results were published in the scientific peer-reviewed Journal of International Immunopharmacology in an article titled "CEL-2000: A Therapeutic Vaccine for Rheumatoid Arthritis Arrests Disease Development and Alters Serum Cytokine / Chemokine Patterns in the Bovine Collagen Type II Induced Arthritis  in the DBA Mouse Model" with lead author Dr. Fri, 19 Feb 2010 18:04:33 Etc/GMT Liberty Analytics Co. Initiates Independent Research Coverage On CEL-SCI Corporation (GlobeNewswire) Thu, 18 Feb 2010 14:00:00 Etc/GMT Wed, 17 Feb 2010 20:22:44 Etc/GMT Wed, 17 Feb 2010 14:00:00 Etc/GMT Tue, 16 Feb 2010 17:05:15 Etc/GMT Tue, 16 Feb 2010 14:00:00 Etc/GMT CEL-SCI Corporation reports financial results for the quarter ended December 31, 2009. Fri, 12 Feb 2010 22:16:36 Etc/GMT Thu, 11 Feb 2010 11:36:55 Etc/GMT Thu, 11 Feb 2010 11:36:55 Etc/GMT Thu, 11 Feb 2010 11:32:20 Etc/GMT Wed, 10 Feb 2010 11:11:30 Etc/GMT Wed, 10 Feb 2010 11:11:30 Etc/GMT Wed, 3 Feb 2010 14:00:00 Etc/GMT CEL-SCI Corporation announced that Geert Kersten, Chief Executive Officer, will be presenting at the 2010 BIO CEO & Investor Conference.  Hosted by the Biotechnology Industry Organization , the conference will take place February 8-9 at the Waldorf=Astoria in New York. Mon, 1 Feb 2010 11:01:31 Etc/GMT Fri, 29 Jan 2010 22:28:46 Etc/GMT Mon, 25 Jan 2010 13:30:00 Etc/GMT |
Daily Blog
 
Newsletter
Editions To subscribe to our newsletter, please enter your email address below. 
Market Summary
|
